Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 381.03M | 363.71M | 305.21M | 245.36M | 188.46M | 164.41M |
Gross Profit | 290.20M | 277.96M | 239.63M | 190.23M | 144.31M | 124.54M |
EBITDA | -930.50M | -814.14M | -660.18M | -429.44M | -375.09M | -250.37M |
Net Income | -1.01B | -913.77M | -749.57M | -481.53M | -434.65M | -294.09M |
Balance Sheet | ||||||
Total Assets | 1.80B | 2.03B | 1.33B | 1.66B | 1.24B | 796.15M |
Cash, Cash Equivalents and Short-Term Investments | 1.20B | 1.43B | 780.45M | 1.15B | 716.78M | 532.76M |
Total Debt | 1.14B | 45.49M | 1.20B | 1.18B | 612.27M | 404.84M |
Total Liabilities | 1.70B | 1.74B | 1.66B | 1.57B | 833.04M | 520.27M |
Stockholders Equity | 99.16M | 285.38M | -331.92M | 87.95M | 410.47M | 275.88M |
Cash Flow | ||||||
Free Cash Flow | -789.25M | -705.80M | -549.53M | -410.32M | -370.59M | -226.17M |
Operating Cash Flow | -761.93M | -683.88M | -536.25M | -400.44M | -363.30M | -219.35M |
Investing Cash Flow | -798.08M | -583.17M | -223.60M | -34.58M | -64.28M | -6.82M |
Financing Cash Flow | 1.37B | 1.34B | 168.44M | 793.27M | 612.55M | 271.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $12.82B | 11.34 | 19.94% | ― | 19.85% | 21.16% | |
74 Outperform | $13.23B | 211.54 | 0.47% | ― | 17.13% | -88.78% | |
72 Outperform | $7.76B | 63.55 | 21.52% | ― | 30.93% | 11.78% | |
71 Outperform | $10.58B | 20.47 | 9.64% | ― | 17.99% | 152.10% | |
63 Neutral | $14.05B | ― | -8.58% | ― | 46.62% | 50.50% | |
56 Neutral | $18.90B | ― | -320.20% | ― | 20.77% | -13.60% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% |
On June 11, 2025, Insmed announced the commencement and pricing of a public offering of its common stock, aiming to raise $650 million, with an option for underwriters to purchase additional shares. The offering, managed by Goldman Sachs and Leerink Partners, is expected to generate approximately $716.3 million in net proceeds, potentially impacting Insmed’s financial position and market operations.
The most recent analyst rating on (INSM) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
On June 10, 2025, Insmed announced positive topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension. The study, which met its primary and all secondary efficacy endpoints, demonstrated a 35% placebo-adjusted reduction in pulmonary vascular resistance and significant improvements in other key metrics. These results underscore TPIP’s potential as a highly effective, once-daily prostanoid therapy. Following these findings, Insmed plans to engage with the FDA to design a Phase 3 trial and aims to initiate further studies in late 2025 and early 2026. The announcement marks a significant advancement in PAH treatment, potentially impacting the company’s market positioning and offering new hope for patients.
The most recent analyst rating on (INSM) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
On June 6, 2025, Insmed Incorporated completed the redemption of its 0.75% Convertible Senior Notes due 2028. The redemption involved paying cash for outstanding notes totaling $1,965,204.69, fulfilling the terms of the Indenture agreement.
The most recent analyst rating on (INSM) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
On May 15, 2025, Insmed Incorporated, a company in the healthcare industry, held its annual meeting where shareholders approved several key proposals. These included the election of Class I directors, an advisory vote on executive compensation, the ratification of Ernst & Young LLP as the independent accounting firm, and the approval of Amendment No. 2 to the 2019 Incentive Plan. The approval of these proposals, particularly the amendment to the incentive plan, is expected to impact the company’s strategic direction and governance, reflecting shareholder support for the company’s leadership and future initiatives.
The most recent analyst rating on (INSM) stock is a Buy with a $72.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.
On April 16, 2025, J. Drayton Wise resigned as Chief Commercial Officer of Insmed Incorporated for personal and medical reasons, effective immediately. His resignation was not due to any issues with the company’s financial or operational results. Mr. Wise will continue to provide consulting services to Insmed until December 31, 2025, with possible extensions. He will receive a monthly consulting fee and his equity awards will continue to vest during this period.